uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed outlook. Financial health shows increased cash reserves due to public offerings, but expenses have risen. Product updates include progress in trials but also a pause due to adverse events. The Q&A highlights regulatory challenges and uncertainties in trial designs. While there is potential for market expansion, lack of clear guidance and unresolved FDA concerns temper optimism. Overall, the sentiment remains neutral due to mixed signals from financial health and regulatory hurdles.
Key Financial Performance
Revenue for the year ended December 31, 2025 $16.1 million compared to $27.1 million in 2024, a decrease of $11 million primarily driven by a $10.7 million decrease in collaboration revenue and a $6.1 million decrease in contract manufacturing revenues, offset by a $5.8 million increase in license revenues.
Cost of contract manufacturing revenues Nil for the year ended December 31, 2025, compared to $17.1 million in 2024, following the divestment of the Lexington facility in 2024.
Research and development expenses $140.7 million for the year ended December 31, 2025, compared to $143.8 million in 2024, a decrease of $3.1 million primarily driven by a $26 million decrease in total other research and development expenses, offset by a $22.9 million increase in total direct research and development expenses.
Selling, general and administrative expenses $65.5 million for the year ended December 31, 2025, compared to $52.7 million in 2024, an increase of $12.8 million primarily driven by a $9.4 million increase in professional fees, a $3.6 million increase in employee and contractor-related expenses, and a $2.8 million increase in other expenses.
Cash, cash equivalents and investment securities $622.5 million as of December 31, 2025, compared with $367.5 million as of December 31, 2024, a net increase primarily attributable to proceeds of approximately $404.2 million raised through public offerings of ordinary shares and prefunded loans.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AMT-130: A novel one-time administered treatment for Huntington's disease. Demonstrated statistically significant slowing of disease progression in Phase I/II study. However, the FDA recommended a Phase III randomized double-blind sham surgery-controlled study for further evidence. Regulatory discussions are ongoing, with plans for a 4-year analysis in Q3 2026.
AMT-191: Gene therapy for Fabry disease. Preliminary data showed elevated alpha-Gal A enzyme activity and successful withdrawal from enzyme replacement therapy for all 11 patients. Dosing paused at mid and high doses due to dose-limiting toxicity in two patients.
AMT-260: Gene therapy for mesial temporal lobe epilepsy. Initial data showed reduction in seizure frequency with no serious adverse events. Enrollment in the second cohort is ongoing, with updates expected in Q2 2026.
Huntington's Disease (HD) Market: Expanded engagement with U.S. and ex-U.S. regulators and healthcare providers. Actively pursuing named patient and early access programs outside the U.S. to expedite access to AMT-130.
Fabry Disease Market: Positioning AMT-191 as a one-time gene therapy to compete with chronic enzyme replacement therapies.
Temporal Lobe Epilepsy Market: Targeting patients with drug-resistant epilepsy through AMT-260, addressing unmet needs in seizure reduction and quality of life.
Financial Position: Cash, cash equivalents, and investment securities totaled $622.5 million as of December 31, 2025, ensuring funding into the second half of 2026.
R&D Expenses: Decreased by $3.1 million year-over-year, primarily due to reduced costs from the 2024 divestiture of the Lexington manufacturing operation.
Selling, General, and Administrative Expenses: Increased by $12.8 million year-over-year, driven by preparation for AMT-130 commercialization and professional fees.
Regulatory Strategy: Focused on engaging with U.S. and ex-U.S. regulatory authorities to define pathways for AMT-130 approval, leveraging natural history data to address FDA feedback.
Pipeline Development: Advancing AMT-130, AMT-191, and AMT-260 with plans for further data generation and regulatory discussions in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The FDA has strongly recommended a Phase III randomized double-blind sham surgery-controlled study for AMT-130, which could delay the approval process. The company disagrees with the FDA's interpretation of the Phase I/II data, creating uncertainty around the regulatory pathway.
Clinical Trial Challenges: The FDA highlighted the absence of treatment effects relative to sham subjects in the U.S. Phase I/II study after 12 months, raising concerns about the efficacy of AMT-130 in the short term. Additionally, the company faces challenges in designing a feasible and ethical Phase III trial.
Patient Recruitment and Retention: A multiyear sham-controlled study could impose significant risks and burdens on patients, potentially affecting recruitment and retention rates. The HD patient community has expressed concerns about the ethical implications of such a trial design.
Financial Risks: Revenue decreased from $27.1 million in 2024 to $16.1 million in 2025, driven by declines in collaboration and contract manufacturing revenues. Increased expenses for commercialization preparation and professional fees have also impacted financials.
Safety Concerns: In the Fabry disease program, two patients experienced dose-limiting toxicities, leading to a pause in dosing at mid and high doses. Additionally, a serious adverse event related to AMT-162 in the ALS program has resulted in a voluntary enrollment and treatment hold.
Market Access and Competition: The company faces challenges in securing regulatory approvals and market access for AMT-130 and other pipeline products, especially in competitive markets like Fabry disease and epilepsy.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
AMT-130 for Huntington's Disease: The company is focused on engaging with the FDA to define a clear regulatory path forward for AMT-130. They are evaluating the FDA's recommendation for a Phase III randomized double-blind sham surgery-controlled study while also considering alternative approaches leveraging natural history data. A Type B meeting is planned for Q2 2026 to discuss Phase III study designs. Additionally, a 4-year analysis of Phase I/II data is expected in Q3 2026 to further assess the therapy's durability and magnitude of effect. Ex-U.S. regulatory discussions are ongoing, with potential opportunities for expedited approval in certain markets.
AMT-191 for Fabry Disease: The company reported durable dose-dependent elevation in alpha-Gal A enzyme activity across three dose levels, with all 11 patients successfully withdrawn from enzyme replacement therapy. However, dosing at mid and high doses is paused due to observed dose-limiting toxicities. The company is evaluating the safety profile and plans to continue advancing the program.
AMT-260 for Mesial Temporal Lobe Epilepsy: Enrollment in the second cohort is expected to be completed by mid-2026. An update on the first cohort's safety, tolerability, and seizure frequency outcomes is planned for Q2 2026. The company sees significant market opportunity for this gene therapy in addressing drug-resistant epilepsy.
AMT-162 for SOD1-ALS: The program remains on voluntary enrollment and treatment hold due to observed dose-limiting toxicity. Data collection and evaluation are ongoing.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there any paths to push the agenda beyond traditional FDA channels and plans for submitting 4-year data?
A:The company is exploring opportunities outside the U.S. regulatory framework, emphasizing patient advocacy and regulatory flexibility for genetically defined diseases. They plan to submit 4-year data to the FDA, including data from 12 patients at 4 years and all patients who have reached 3 years.
Q:Was the morbidity associated with procedures involving burr holes a major sticking point with the FDA?
A:The company stated that the FDA focuses on patient safety and that they have a strong safety profile. They have educated the FDA on volumetric MRI changes and safety events, which are not associated with clinical consequences.
Q:What is the strategy for the Type B meeting and outside the U.S.?
A:The Type B meeting will focus on Phase III trial designs, leveraging the Enroll-HD database to strengthen study designs and minimize patient burden. Outside the U.S., the company is exploring regulatory pathways and early access programs in regions like the U.K. and Europe.
Q:How quickly can the Phase III trial be enrolled, and has this changed partnering decisions outside the U.S.?
A:It is premature to discuss logistics and recruitment timelines for Phase III as the design is not finalized. Partnering decisions outside the U.S. are also premature and depend on the Phase III study design and investment requirements.
Q:What are the potential scenarios for Phase III design, and does the cash runway include this?
A:The company has not finalized discussions with the FDA on Phase III design, including study length and endpoints. The cash runway includes development spend, but specific allocations for Huntington's Phase III are uncertain.
Q:What regions are being considered for regulatory discussions outside the U.S., and what is the status of the epilepsy program?
A:The company is considering regions like the U.K. and Europe for regulatory discussions and early access programs. For the epilepsy program, they will present data on 6 patients from the first dose cohort with 6-month follow-up in Q2.
Q:What is the commercial opportunity for the ex-U.S. market?
A:The company is in the planning phase and considers Roche's approach with ELEVIDYS as a potential model but has not provided specific commercial opportunity estimates.
Q:What are the sticking points with the FDA, and why is a sham-controlled study required?
A:The FDA views the Phase I/II studies as hypothesis-generating and emphasizes the need for a sham-controlled trial for robust evaluation. The company argues for regulatory flexibility and leveraging natural history data for rare diseases like Huntington's.
Q:Is there potential for an accelerated path with a Phase III study based on interim analysis?
A:The FDA has not ruled out the possibility of accelerated approval based on interim analysis, but discussions on Phase III design are still pending.
Q:Was there a lack of biomarker data in discussions with the FDA?
A:The FDA raised concerns about the absence of biomarker data in the small U.S. sham-controlled study over 1 year but has not set specific expectations for 3-year data.
Q:What would be considered too difficult or challenging for patients in a Phase III design?
A:A sham surgery requiring anesthesia and invasive procedures over 2-3 years is considered burdensome. The company aims to design scientifically sound studies that minimize patient burden.
Q:What is the biggest pushback from the FDA regarding the trial design?
A:The FDA seeks to minimize potential bias through a sham-controlled study, despite the availability of robust natural history data. The company argues this does not reflect regulatory flexibility for rare diseases.
Q:Will the company proceed with a sham-controlled pivotal trial if required?
A:The company is committed to pursuing a feasible and ethical sham-controlled trial if supported by the patient community, emphasizing their dedication to bringing AMT-130 to patients.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on Phase III trial design, cash runway allocations for Huntington's Phase III, and commercial opportunity estimates for the ex-U.S. market. They also did not clarify the FDA's specific objections to using natural history data or provide a clear stance on accelerated approval pathways.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
California
Gal enzyme
Grade
HD community
II study
III study
III surgery
Phase II
Phase III
alpha Gal
approach
body
burden
challenge
covariates
development decrease
dose toxicity
durability
elevation
employee contractor
engagement
enzyme activity
evaluation
flexibility
meeting agency
opportunity
patient community
patient mid
reimbursement
replacement therapy
seizure
sham study
share
study AMT
study control
study design
surgery study
term
world
QURE Transcript
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
Unknown5-5
Despite a 15% YoY revenue increase and reduced net loss, the earnings call highlighted significant risks, including regulatory challenges and economic uncertainties, which may offset the positive financial performance. No new partnerships or shareholder return plans were discussed, and the strategic initiatives were unclear. The Q&A provided no additional insights to alter this neutral outlook.
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
Unknown3-2
The earnings call reveals a mixed outlook. Financial health shows increased cash reserves due to public offerings, but expenses have risen. Product updates include progress in trials but also a pause due to adverse events. The Q&A highlights regulatory challenges and uncertainties in trial designs. While there is potential for market expansion, lack of clear guidance and unresolved FDA concerns temper optimism. Overall, the sentiment remains neutral due to mixed signals from financial health and regulatory hurdles.
uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call shows mixed signals: strong cash position and potential for AMT-130, but increased expenses and uncertain regulatory outcomes. The Q&A reveals robust testing and a motivated community for Huntington's, but concerns about dose toxicity and unclear FDA interactions. The strategic plan indicates optimism for future approvals, but the lack of EMA/MHRA engagement and management's evasiveness on key questions temper expectations. Overall, the neutral sentiment reflects positive long-term prospects but short-term uncertainties.
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
Unknown7-29
The earnings call summary shows mixed signals. The basic financial performance is weak due to a significant revenue decline, but the company maintains a strong cash position. Product development is promising with advanced pipeline stages and FDA breakthrough designation. Market strategy and shareholder return plans are unclear or not emphasized. The Q&A reveals optimism in regulatory and commercial prospects but lacks clarity on key metrics like NfL. Given these mixed factors, the stock is likely to remain stable in the short term, leading to a neutral prediction.
QURE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
